TransMedics Group’s (TMDX) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a report published on Wednesday,Benzinga reports.

Separately, Canaccord Genuity Group restated a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

Shares of TMDX opened at $92.31 on Wednesday. The business’s 50-day moving average is $73.65 and its 200-day moving average is $78.82. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of 98.20 and a beta of 2.14. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. Vanguard Group Inc. raised its stake in TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock valued at $226,700,000 after purchasing an additional 40,860 shares during the last quarter. FIL Ltd lifted its stake in shares of TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock valued at $62,372,000 after buying an additional 218,961 shares during the period. Braidwell LP acquired a new stake in TransMedics Group during the fourth quarter worth about $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock valued at $56,307,000 after acquiring an additional 128,474 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after acquiring an additional 349,403 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.